drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Fc-engineered humanized IgG1 anti-CD19 monoclonal antibody given IV; binds CD19 on B cells/leukemic blasts to enhance Fcγ receptor–mediated ADCC and ADCP via NK cells and macrophages and can induce direct apoptosis, leading to depletion of CD19+ cells in B-lineage ALL.
nci_thesaurus_concept_id
C95768
nci_thesaurus_preferred_term
Tafasitamab
nci_thesaurus_definition
An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.
drug_mesh_term
Tafasitamab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Other treatment
drug_delivery_route
Intravenous
drug_mechanism_of_action
Fc‑engineered humanized IgG1 monoclonal antibody against CD19 that binds CD19 on B cells and leukemic blasts and enhances Fcγ receptor–mediated ADCC and ADCP by NK cells and macrophages; can also induce direct apoptosis, resulting in depletion of CD19‑positive cells.
drug_name
Tafasitamab
nct_id_drug_ref
NCT05366218